Cortexyme presents data linking p. gingivalis to elevated levels of phospho-tau217 reinforcing evidence of pathogen as causative agent of alzheimer's disease at aaic 2021

South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx), a company advancing a pivotal trial in alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the presentation of new preclinical data linking p. gingivalis to increased levels of phospho-tau217, an emerging biomarker for alzheimer's disease. this research, along with new baseline data from its pivotal gain trial, is bei
QNCX Ratings Summary
QNCX Quant Ranking